DexCom

YTD

ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE.

CEO

Jacob S. Leach

CEOJacob S. Leach

Employees

11,100

Employees11,100

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1999

Founded1999

Employees

11,100

Employees11,100

DXCM Key Statistics

Market cap

31.86B

Market cap31.86B

Price-Earnings ratio

33.28

Price-Earnings ratio33.28

Dividend yield

—

Dividend yield—

Average volume

2.88M

Average volume2.88M

High today

$84.54

High today$84.54

Low today

$83.08

Low today$83.08

Open price

$84.20

Open price$84.20

Volume

3.49M

Volume3.49M

52 Week high

$92.59

52 Week high$92.59

52 Week low

$54.11

52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $84.41. The company's market cap stands at 31.86B, with a P/E ratio of 33.28.

On 2026-10-08, DexCom(DXCM) stock traded between a low of $83.08 and a high of $84.54. Shares are currently priced at $84.41, which is +1.6% above the low and -0.2% below the high.

DexCom(DXCM) shares are trading with a volume of 3.49M, against a daily average of 2.88M.

During the past year, DexCom(DXCM) stock moved between $54.11 at its lowest and $92.59 at its peak.

DXCM News

Simply Wall St 4h

DexCom Following Citi's Guidance Focus Has Valuation Back In View - Simply Wall Street

...

Simply Wall St 1d

Should Type 2 Care Report Require Action From DexCom Investors?

DexCom published its 2026 “State of Type 2” report and announced a CGM partnership with Team Novo Nordisk, highlighting strong user outcomes alongside ongoing c...

TipRanks 2d

DexCom initiated with an Overweight at Barclays

Barclays initiated coverage of DexCom (DXCM) with an Overweight rating and $115 price target The firm rolled out coverage of the medical suppliers and devices g...

Analyst ratings

84%

of 32 ratings

Buy

84.4%

Hold

15.6%

Sell

More DXCM News

TipRanks 2d

DexCom announces launch of fifth season of Dexcom U

DEXCOM (DXCM) announced the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL program exclusively for college athletes with diabetes. Now...

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.